Hello Everybody It is hard to believe that we are nearly two thirds through the year and what a year it has been. The COVID-19 pandemic has impacted on our seminars and other activities this year and we were disappointed to have to cancel the Whangarei seminar at the last minute with the Auckland lockdown....Continue Reading

This article was originally published by Cure Understanding Smoldering Multiple Myeloma Transcript: Kristie L. Kahl: Can you explain what smoldering myeloma is? Dr. Irene Ghobrial: Many patients come in to see us because they have back pain or anemia or kidney problems; however, if we know that every single patient who comes to see us with multiple...Continue Reading

This article was originally published by AJMC Treatment Evolution in Multiple Myeloma Looking at the current state of multiple myeloma management, experts discuss interest in novel therapies and MRD assessment to guide treatment. Transcript Bruce Feinberg, DO: Hello, and welcome to this AJMC® webcast titled “Changing Patterns of Care in Multiple Myeloma.” I’m Dr Bruce Feinberg from...Continue Reading

This article was originally published by Cancer Network The FDA has approved daratumumab (Darzalex) for use in combination with carfilzomib (Kyprolis) and dexamethasone (DKd) to treat adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 previous lines of therapy, according to the Janssen Pharmaceutical Companies of Johnson & Johnson, the...Continue Reading

This article was originally published by Targeted Oncology As part of a virtual Case Based Peer Perspective event, Jesus G. Berdeja, MC, director of Myeloma Research, Sarah Cannon Research Institute, in Nashville, Tennesee, discussed the treatment options for stage II multilple myeloma, based on a case of a 71-year female patient. Targeted Oncology™: Is this...Continue Reading

This article was originally published by AJMC MRD Should Be More Widely Used in Clinical Care of MM, Report Argues Advances in scientists’ understanding of multiple myeloma (MM) and in the ability to assess minimal residual disease (MRD) have made the metric an important method to track the efficacy of therapy in clinical trial settings....Continue Reading

This article was originally published by Cancer Health New drugs to treat multiple myeloma are producing better results for patients, with fewer side effects. For many patients with multiple myeloma, a new generation of drugs and drug combinations is producing better outcomes and fewer side effects. In recent months, several novel therapies studied and tested...Continue Reading

This article was originally published by Targeted Oncology. C. Ola Landgren, MD, PhD, chief of Myeloma Service and hematologic oncologist at Memorial Sloan Kettering Cancer Center, discusses the use of chimeric antigen receptor (CAR) T cells and CAR natural killer (NK) cells in the multiple myeloma setting. As with every therapy, there are pros and cons...Continue Reading

Hamilton Myeloma Semimar, Saturday 5 September Come along to our Hamilton Myeloma Patient Seminar, hosted by MyelomaNew Zealand and Leukaemia & Blood Cancer New Zealand. During the morning, we will hear from Dr Henry Chan (Waitemata DHB) and Dr Hugh Goodman (Waikato DHB) who will discuss some of the changes to come in 2020 for...Continue Reading

Blenrep, an antibody-drug conjugate, is the first drug approved for multiple myeloma that targets the antigen BCMA. Several other companies are also developing BCMA-targeting therapies for the blood cancer, including CAR-T cells and bispecific antibodies. The Food and Drug Administration has granted accelerated approval to a drug for multiple myeloma that is the first of...Continue Reading